Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
13C-labeled lactate is a stable isotope tracer compound consisting of lactate labeled with the non-radioactive carbon-13 isotope. Developed and studied by researchers at Karolinska University Hospital and Karolinska Institutet, it is utilized as an investigational metabolic tracer rather than a therapeutic agent. The compound is administered intravenously (typically as a single bolus) to characterize lactate kinetics, specifically the rate of appearance and metabolic clearance in the blood of critically ill ICU patients with organ failure. By tracking the isotope, researchers can perform non-compartmental modeling to understand altered lactate metabolism during critical illness without exposing patients to ionizing radiation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 13C-labeled lactate.